^
    Back
    Association details:
    Biomarker:NRAS mutation
    Cancer:Solid Tumor
    Drug:Koselugo (selumetinib) (MEK inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer

    Excerpt:
    ...Complete Remission Rate (Expressed as Percentage of Patients in Complete Remission) at 18 Months Post-RAI Treatment; Subgroup Analysis BRAF/NRAS Mutation Positive`Clinical Remission Rate (Expressed as Percentage of Patients in Clinical Remission) at 18 Months Post-RAI Treatment; ITT Analysis Set`Clinical Remission Rate (Expressed as Percentage of Patients in Clinical Remission) at 18 Months Post-RAI Treatment; Subgroup Analysis BRAF/NRAS Mutation Positive...
    Trial ID:
    ASTRA
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma

    Excerpt:
    ...- Must have a V600E or V600K BRAF-mutated tumor, or a NRAS mutation at condons 12, 13, or 61...
    Trial ID:
    NCT00866177
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Randomised Study to Compare the Efficacy of AZD6244 vs TMZ

    Excerpt:
    ...Assessment of the safety and tolerability of AZD6244`Investigation of the pharmacokinetics of AZD6244`Assessment of the efficacy of AZD6244 versus temozolomide in patients who are BRAF and BRAF and /or NRAS mutation positive...
    Trial ID:
    NCT00338130
    Less C2 evidence
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASCO 2021
    Title:

    Selumetinib in patients with tumors with MAPK pathway alterations: Results from Arm E of the NCI-COG pediatric MATCH trial.

    Published date:
    05/19/2021
    Excerpt:
    Selumetinib did not result in tumor regression in this cohort of children and young adults with treatment-refractory tumors with activating MAPK pathway alterations. 
    DOI:
    10.1200/JCO.2021.39.15_suppl.10008
    Trial ID:
    MATCH